MC2 Plots Course For Topical Psoriasis Drug Launch After Positive Phase III Data

15:29 EDT 21 Aug 2018 | SCRIP

The Danish company is planning to file an NDA with the US FDA in 2019 after reporting positive Phase III...

More From BioPortfolio on "MC2 Plots Course For Topical Psoriasis Drug Launch After Positive Phase III Data"